Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer

Cancer

Volumn 110, Issue 10, 2007, Pages 2210-2217

  Sommers, Benjamin D ^a   Beard, Clair J ^a   D'Amico, Anthony V ^a   Dahl, Douglas ^b   Kaplan, Irving ^c   Richie, Jerome P ^a   Zeckhauser, Richard J ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Decision analysis; Prostate cancer; Quality adjusted life year (QALY)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; DECISION MAKING; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HEALTH SURVEY; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MODEL; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; WATCHFUL WAITING;

AGED; DECISION SUPPORT TECHNIQUES; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS;

EID: 36049029939     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23028     Document Type: Article

References (29)

1. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977-1984.
2. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 1993;269: 2650-2658.
3. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 1997;12:299-305.
4. Alibhai SMH, Naglie G, Nam R, Trachtenberg J, Krahn M. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 2003;21:3318-3327.
5. Cowen ME, Miles BJ, Cahill DF, et al. The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making. 1998;18:376-380.
6. Alibhai SMH, Leach M, Tomlinson G, et al. Rethinking 30-day mortality risk after radical prostatectomy. Urology. 2006;68:1057-1060.
7. Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer: multi-institutional pooled analysis. JAMA. 1996;276: 615-619.
8. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
9. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327-333. Epub 2006 Nov 2.
10. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1274-1276.
11. Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol. 2006;175:907-912.
12. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Ins. 2005; 97:1236-1237.
13. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
14. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21:3979-3986.
15. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790-796.
16. Arias E. United States Life Tables, 2002.National Vital Statistics Reports. Vol. 53, no 6. Hyattsville, MD: National Center for Health Statistics; 2004.
17. Shepard D, Zeckhauser R. Where now for saving lives? Law Contemp Probl. 1976;40:5-45.
18. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:214-246.
19. Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma. Cancer. 2005;104:467-478.
20. Albertsen PC, Nease RF, Potosky AL. Assessment of patient preferences among men with prostate cancer. J Urol. 1998; 159:158-163.
21. Krahn M, Ritvo P, Irvine J, et al. Construction of the Patient-Oriented Prostate Utility Scale (PORPUS): a multi-attribute health state classification system for prostate cancer. J Clin Epidemiol. 2000;53:920-930.
22. Foundation for Informed Medical Decision Making. Treatment Choices for Prostate Cancer: A Shared Decision-Making Program. Boston: Health Dialog; 2003.
23. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43:347-355.
24. Barry M. The PSA conundrum. Arch Intern Med. 2006; 166:7-8.
25. Elkin EB, Cowen ME, Cahill D, Steffel M, Kattan MW. Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example. Med Decis Making. 2004;24:504-510.
26. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science. 1981;211:453-458.
27. Barry M. Health decision aids to facilitate shared decision making in office practice. Ann Intern Med. 2002;136:127-135.
28. Denberg TD, Melhado TV Steiner JF. Patient treatment preferences in localized prostate carcinoma: the influence of emotion, misconception, and anecdote. Cancer. 2006;107: 620-630.
29. Fowler FJ, Collins MM, Albertsen PC, et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283:3217-3222.